Show Filters

Searches all publications.

Search Fulltext



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-07-20
    E.g., 2018-07-20


12212 items
4:51 PM, Jul 13, 2018  |  BC Extra | Financial News

Roivant’s urology subsidiary files for $150M IPO

Urovant Sciences Ltd. (London, U.K) proposed Friday to raise up to $150 million in an IPO on NASDAQ underwritten by J.P. Morgan, Jefferies and Cowen. The urology play is a wholly owned subsidiary of Roivant...
11:14 AM, Jul 13, 2018  |  BC Extra | Financial News

Follow-on roundup: Myovant, CytomX, Spero

Myovant Sciences Ltd. (NYSE:MYOV), CytomX Therapeutics Inc. (NASDAQ:CTMX) and Spero Therapeutics Inc. (NASDAQ:SPRO) each priced follow-ons late Thursday, raising a total of $275 million. Myovant raised $75 million through the sale of 3.3 million shares at...
5:33 PM, Jul 12, 2018  |  BC Extra | Financial News

MS play Octave adds Scangos to board, raises $14M series A

Multiple sclerosis company Octave Bioscience Inc. (Menlo Park, Calif.) raised $14 million in a series A round led by new investor BlueCross BlueShield Venture Partners. Echo Health Ventures, Section 32 and other new and existing...
12:27 PM, Jul 12, 2018  |  BC Extra | Financial News

Haitong leads Orig3n's series B

Regenerative medicine company Orig3n Inc. (Boston, Mass.) said it had an initial close of a series B round led by Haitong International. Orig3n did not disclose how much it raised in the initial close; however,...
11:36 AM, Jul 12, 2018  |  BC Extra | Financial News

Idorsia raises $511.9M in dual offerings

Idorsia Ltd. (SIX:IDIA) raised CHF505.2 million ($511.9 million) in a pair of private placements underwritten by Credit Suisse, Goldman Sachs and Octavian. Idorsia raised CHF305.2 million ($309.2 million) through the sale of 11.9 million shares at...
11:30 AM, Jul 12, 2018  |  BC Extra | Financial News

Assembly raises $144M follow-on

Assembly Biosciences Inc. (NASDAQ:ASMB) raised $144 million late Wednesday through the sale of 4 million shares at $36 in a follow-on underwritten by Jefferies, Leerink, William Blair, Mizuho Securities, Baird and National Securities Corp. The price...
8:35 AM, Jul 12, 2018  |  BC Extra | Financial News

With $132M series A, Compass points toward the clinic

Bispecific antibody play Compass Therapeutics LLC (Cambridge, Mass.) raised $49 million Thursday in the final tranche of its series A round, bringing the round's total to $132 million. OrbiMed Advisers led the round. F-Prime Capital Partners,...
12:01 AM, Jul 11, 2018  |  BC Extra | Financial News

Forbion raises €270M, surpassing target for fourth fund

Forbion Capital Partners raised €270 million ($317.8 million) toward Forbion IV, surpassing its target of €250 million ($294.2 million). The firm said the fund will have a "sharper focus" on biotech investments than Forbion Capital Fund...
4:35 PM, Jul 09, 2018  |  BC Extra | Financial News

Abingworth closes BioVentures VII fund at $315M

Abingworth Management Ltd. closed its BioVentures VII fund at $315 million, exceeding the fund's $300 million target. Funds will be invested in the U.S. and Europe. Abingworth's therapeutic interests for BioVentures VII include next-generation cell therapies,...
4:04 PM, Jul 09, 2018  |  BC Extra | Financial News

Wellcome launches £250M blue sky fund

The Wellcome Trust launched the Leap Fund with £250 million ($333.5 million) to back life sciences projects deemed too risky to receive funding through traditional routes. Wellcome Director Jeremy Farrar told BioCentury the five-year, not-for-profit...